Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Muhit Ozcan, Won Seog Kim, Huilai Zhang, Maria Bouzani, Zsolt Nagy, Hun Chuah, Gilles Salles, Edwin E. Jeng, Jiangeng Huang, Mariana Sacchi, Yajian Jiang, Adrian Minson

Blood (2024) 144 (Supplement 1): 4502.1.

https://doi.org/10.1182/blood-2024-198700

Published: 2024

Journal Articles

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 578.

https://doi.org/10.1182/blood-2024-200271

Published: 2024

Journal Articles

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study

Pier Luigi Zinzani, Juan Carlos Dupont, Alessandra Tucci, Jing Yang, Yan Xu, Siyang Leng, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 3016.

https://doi.org/10.1182/blood-2024-201646

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Blood (2024) 144 (Supplement 1): 3046.

https://doi.org/10.1182/blood-2024-200323

Published: 2024

Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2024-201522

Published: 2024

Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera

Blood (2023) 142 (Supplement 1): 3082.

https://doi.org/10.1182/blood-2023-182119

Published: 2023

Journal Articles

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Maria Sureda Balari, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Ozcan, Amos Odeleye-Ajakaye, Nishitha Reddy, Patricia Marinello, Jane N. Winter

Blood (2023) 142 (Supplement 1): 3068.

https://doi.org/10.1182/blood-2023-181171

Published: 2023

Journal Articles

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4442.

https://doi.org/10.1182/blood-2023-186800

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Derya Koyun, Uğur Şahin, Güldane Cengiz Seval, Deniz Gören Şahin, Ayla Gökmen, Sinem Civriz Bozdağ, Selami Kocak Toprak, Pervin Topçuoğlu, Meltem Kurt Yüksel, Önder Arslan, Taner Demirer, Günhan Gürman, Osman İlhan, Meral Beksac, Muhit Özcan, Mutlu Arat

Blood (2023) 142 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2023-182741

Published: 2023

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Journal Articles

Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least One Prior Therapy

David Lavie, Muhit Ozcan, Arvind Chaudhry, Xuan Zhou, Ima Paydar, Mohammed Z.H. Farooqui, Paolo Ghia

Blood (2023) 142 (Supplement 1): 3287.

https://doi.org/10.1182/blood-2023-180920

Published: 2023

Journal Articles

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2023) 142 (2): 141–145.

https://doi.org/10.1182/blood.2022019340

Published: 2023

Journal Articles

Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Hulya Yilmaz, Guldane Cengiz, Bulent Karakaya, Gul Yavuz, Merve Aydogan, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topçuoğlu, Onder Arslan, Muhit Ozcan, Osman Ilhan, Meral Beksac

Blood (2022) 140 (Supplement 1): 4369–4370.

https://doi.org/10.1182/blood-2022-170132

Published: 2022

Journal Articles

Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Burhan Ferhanoglu, Zafer Gulbas, Ant Uzay, Muhit Özcan, Fahir Ozkalemkas, Mehmet Sinan Dal, Hakan Kalyon, Olga Meltem Akay, Burak Deveci, Huseyin Bekoz, Omur Gokmen Sevindik, Tayfur Toptas, Asu Fergun Yilmaz, Derya Koyun, Nihan Alkis, Elif Birtas Atesoglu

Blood (2022) 140 (Supplement 1): 6704–6705.

https://doi.org/10.1182/blood-2022-165385

Published: 2022

Journal Articles

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Sureda, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Özcan, Amos Odeleye-Ajakaye, Uzor C. Ogbu, Akash Nahar, Jane N. Winter

Blood (2022) 140 (Supplement 1): 1759–1760.

https://doi.org/10.1182/blood-2022-163787

Published: 2022

Journal Articles

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

Pier Luigi Zinzani, Muhit Özcan, Marcelo Capra, Armando Santoro, Panayiotis Panayiotidis, Krimo Bouabdallah, Wojciech Jurczak, Charles Phelps, Florian JR Hiemeyer, Lidia Mongay Soler, Jose Garcia-Vargas, Barrett H. Childs, Georg Lenz, Matthew J. Matasar, Martin Dreyling

Blood (2022) 140 (Supplement 1): 6470–6473.

https://doi.org/10.1182/blood-2022-167368

Published: 2022

Journal Articles

The Impact of CD34+ Cell and Immunefector Cell Dose on Transplant Outcomes

Derya Koyun, Guldane Cengiz, Sinem Civriz Bozdag, Selami Kocak Toprak, Pervin Topçuoğlu, Muhit Özcan, Onder Arslan, Taner Demirer, Osman İlhan, Gunhan Gurman, Meral Beksac, Meltem Kurt Yuksel

Blood (2022) 140 (Supplement 1): 12673–12674.

https://doi.org/10.1182/blood-2022-155998

Published: 2022

Journal Articles

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew K. McMillan, Muhit Özcan, Violaine Safar, Gilles Salles, Jamie Hirata, Annie Yang, Lisa Musick, Matthew J. Matasar

Blood (2022) 140 (Supplement 1): 9464–9467.

https://doi.org/10.1182/blood-2022-157679

Published: 2022

Journal Articles

The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Osman Ilhan, Guldane Cengiz Seval, Sinem Civriz Bozdag, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Muhit Özcan, Taner Demirer, Gunhan Gurman, Meral Beksac

Blood (2021) 138 (Supplement 1): 4906.

https://doi.org/10.1182/blood-2021-153905

Published: 2021

Journal Articles

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Pier Luigi Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Waleswski, Alejandro Majlis, Laura Fogliatto, Alejandro Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Özcan, Guilherme Fleury Perini, Gilles Salles, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand

Blood (2021) 138 (Supplement 1): 306.

https://doi.org/10.1182/blood-2021-148082

Published: 2021

NARROW

Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Nemtabrutinib, a Noncovalent Reversible BTK Inhibitor in Relapsed or Refractory Marginal Zone Lymphoma: Results from the Phase 2 Bellwave-003 Study

Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma: Keynote-B68 Update

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

Efficacy and Safety of Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Keynote-B68: Updated Efficacy and Safety of Pembrolizumab Every Six Weeks in Relapsed/Refractory Classical Hodgkin Lymphoma or Primary Mediastinal B-Cell Lymphoma

Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Bellwave-010: Phase 3, Open-Label, Randomized Study of Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least One Prior Therapy

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis

Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib

The Impact of CD34+ Cell and Immunefector Cell Dose on Transplant Outcomes

Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Final Results of a Phase Ib/II Randomized Study and Single-Arm Extension (Ext) Study

The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Final Analysis of Keynote-170: Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only